维持性血液透析患者的静脉铁治疗
这项多中心、开放标签、盲法终点评估的随机对照试验纳入2141例维持性血液透析成人,比较主动高剂量静脉铁蔗糖(400 mg/月,除非铁蛋白>700 μg/L或转铁蛋白饱和度≥40%)与反应性低剂量方案(0–400 mg/月,触发条件为铁蛋白<200 μg/L或转铁蛋白饱和度<20%)。中位随访2.1年,高剂量组主要复合终点(非致死性心肌梗死、非致死性卒中、心力衰竭住院或死亡)发生率为29.3%,低剂量组为32.3%(HR 0.85;95%CI 0.73–1.00;非劣效性P<0.001;优效性P=0.04)。高剂量组促红细胞生成素月剂量中位数更低(29,757 IU vs 38,805 IU;中位差-7539 IU;95%CI -9485至-5582),两组感染率相同。
要点
- 维持性血液透析成人中,主动高剂量静脉铁蔗糖方案(400 mg/月,铁蛋白>700 μg/L或转铁蛋白饱和度≥40%时暂停)主要复合终点发生率为29.3%,反应性低剂量组为32.3%(HR 0.85;95%CI 0.73–1.00;优效性P=0.04)。
- 高剂量组促红细胞生成素月剂量中位数为29,757 IU,低剂量组为38,805 IU(中位差-7539 IU;95%CI -9485至-5582)。
- 高剂量组实际接受静脉铁月剂量中位数为264 mg(四分位距200–336),低剂量组为145 mg(四分位距100–190)。
- 重复事件分析中,高剂量组429次事件,低剂量组507次事件(率比0.77;95%CI 0.66–0.92)。
- 两组感染率相同。
适用人群与场景
- 接受维持性血液透析的成人。
诊断标准与关键阈值
- 高剂量组给药条件:每月静脉铁蔗糖400 mg,除非铁蛋白浓度>700 μg/L或转铁蛋白饱和度≥40%。
- 低剂量组给药触发条件:铁蛋白浓度<200 μg/L或转铁蛋白饱和度<20%时给予0–400 mg/月。
处置流程与药物剂量
- 高剂量组:静脉铁蔗糖400 mg/月主动给药,铁蛋白>700 μg/L或转铁蛋白饱和度≥40%时不给药。
- 低剂量组:铁蛋白<200 μg/L或转铁蛋白饱和度<20%时触发静脉铁蔗糖0–400 mg/月反应性给药。
研究设计与关键结果
- 多中心、开放标签、盲法终点评估随机对照试验,纳入2141例维持性血液透析成人(高剂量组1093例,低剂量组1048例),中位随访2.1年。
- 主要复合终点(非致死性心肌梗死、非致死性卒中、心力衰竭住院或死亡)高剂量组320例(29.3%)vs低剂量组338例(32.3%),HR 0.85(95%CI 0.73–1.00),非劣效性P<0.001,优效性P=0.04。
- 重复事件分析:高剂量组429次事件 vs 低剂量组507次事件,率比0.77(95%CI 0.66–0.92)。
- 促红细胞生成素月剂量中位数:高剂量组29,757 IU vs低剂量组38,805 IU,中位差-7539 IU(95%CI -9485至-5582)。
- 静脉铁月剂量中位数:高剂量组264 mg(四分位距200–336)vs低剂量组145 mg(四分位距100–190)。
- 感染率两组相同。
证据类型、等级与局限
- 证据类型:多中心、开放标签、盲法终点评估随机对照试验。
- 非劣效性界值:主要终点风险比95%CI上限不超过1.25。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在维持性血液透析成人中,主动高剂量静脉铁蔗糖方案(400 mg/月,铁蛋白>700 μg/L或转铁蛋白饱和度≥40%时暂停)较高剂量组主要复合终点事件更少(29.3% vs 32.3%;HR 0.85;95%CI 0.73–1.00),且促红细胞生成素用量更低。
- 该方案不适用于铁蛋白>700 μg/L或转铁蛋白饱和度≥40%时的给药。
- 两组感染率相同。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intravenous iron is a standard treatment for patients undergoing hemodialysis, but comparative data regarding clinically effective regimens are limited.
METHODS: In a multicenter, open-label trial with blinded end-point evaluation, we randomly assigned adults undergoing maintenance hemodialysis to receive either high-dose iron sucrose, administered intravenously in a proactive fashion (400 mg monthly, unless the ferritin concentration was >700 μg per liter or the transferrin saturation was ≥40%), or low-dose iron sucrose, administered intravenously in a reactive fashion (0 to 400 mg monthly, with a ferritin concentration of <200 μg per liter or a transferrin saturation of <20% being a trigger for iron administration). The primary end point was the composite of nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, or death, assessed in a time-to-first-event analysis. These end points were also analyzed as recurrent events. Other secondary end points included death, infection rate, and dose of an erythropoiesis-stimulating agent. Noninferiority of the high-dose group to the low-dose group would be established if the upper boundary of the 95% confidence interval for the hazard ratio for the primary end point did not cross 1.25.
RESULTS: A total of 2141 patients underwent randomization (1093 patients to the high-dose group and 1048 to the low-dose group). The median follow-up was 2.1 years. Patients in the high-dose group received a median monthly iron dose of 264 mg (interquartile range [25th to 75th percentile], 200 to 336), as compared with 145 mg (interquartile range, 100 to 190) in the low-dose group. The median monthly dose of an erythropoiesis-stimulating agent was 29,757 IU in the high-dose group and 38,805 IU in the low-dose group (median difference, -7539 IU; 95% confidence interval [CI], -9485 to -5582). A total of 320 patients (29.3%) in the high-dose group had a primary end-point event, as compared with 338 (32.3%) in the low-dose group (hazard ratio, 0.85; 95% CI, 0.73 to 1.00; P<0.001 for noninferiority; P=0.04 for superiority). In an analysis that used a recurrent-events approach, there were 429 events in the high-dose group and 507 in the low-dose group (rate ratio, 0.77; 95% CI, 0.66 to 0.92). The infection rate was the same in the two groups.
CONCLUSIONS: Among patients undergoing hemodialysis, a high-dose intravenous iron regimen administered proactively was superior to a low-dose regimen administered reactively and resulted in lower doses of erythropoiesis-stimulating agent being administered. (Funded by Kidney Research UK; PIVOTAL EudraCT number, 2013-002267-25 .).
参考来源
- Macdougall IC, White C, Anker SD, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. N Engl J Med. 2018. PMID: 30365356. doi:10.1056/NEJMoa1810742
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。